Anti-Carbamylated Protein Antibodies in ACPA-Negative and ACPA-Positive Patients with Rheumatoid Arthritis von Dibrov, D. A., Avdeeva, A. S., Diatroptov, M. E., Nasonov, E. L.

Volltext

New directions of pharmacotherapy of immune - inflammatory rheumatic diseases von Nasonov, E L

Volltext

Clinical Features of ACPA-Negative and ACPA-Positive Variants of Rheumatoid Arthritis von Dibrov, D. A., Avdeeva, A. S., Rybakova, V. V., Demidova, N. V., Nasonov, E. L.

Volltext

The Prevalence and Factors Associated with Coronary Heart Disease in Patients with Gout von Markelova, E. L., Eliseev, M. S., Il’inykh, E. V., Glukhova, S. I., Nasonov, E. L.

Volltext

Atherosclerosis: perspectives of anti-inflammatory therapy von Nasonov, E L, Popkova, T V

Volltext

Coronavirus disease 2019 (COVID-19) pandemic and autoimmune rheumatic diseases: Outcomes and prospects von Nasonov, E. L.

Volltext

Rheumatoid arthritis: achievements and unresolved issues von Nasonov, E L, Lila, A M

Volltext

Modern concept of autoimmunity in rheumatology von Nasonov, E. L.

Volltext

Advantages of therapy with sodium glucose cotransporter type 2 inhibitors in patients with type 2 diabetes mellitus in combination with hyperuricemia and gout von Panevin, T. S., Eliseev, M. S., Shestakova, M., Nasonov, E. L.

Volltext

Depression and severity of articular destruction in patients with rheumatoid arthritis von Abramkin, A. A., Lisitsyna, T. A., Veltishchev, D. Yu, Seravina, O. F., Kovalevskaya, O. B., Glukhova, S., Nasonov, E. L.

Volltext

Coronavirus disease 2019 (COVID-19) and autoimmunity von Nasonov, E. L.

Volltext

The prospects of interleukin-6 inhibition in rheumatoid arthritis: Olokizumab (novel monoclonal antibodies to IL-6) von Nasonov, E. L., Feist, Eugen

Volltext

Results of one-year treat-to-target strategy in early psoriatic arthritis: data of an open-label REMARCA study von Korotaeva, T V, Loginova, E Yu, Getiya, T S, Nasonov, E L

Volltext

Effectiveness and safety of selective and non - selective factor Xa inhibitors in antiphospholipid syndrome and systemic lupus erythematosus: anti - Xa - activity range von Seredavkina, N V, Reshetnyak, T M, Satybaldyeva, M A, Kashnikova, L N, Temnikova, T A, Nasonov, E L

Volltext

IMMUNOPATHOLOGY AND IMMUNOPHARMACOTHERAPY OF CORONAVIRUS DISEASE 2019 (COVID-19): FOCUS ON INTERLEUKIN 6 von Nasonov, E. L.

Volltext

CORONAVIRUS DISEASE 2019 (COVID-19): A RHEUMATOLOGIST’S THOUGHTS von Nasonov, E. L.

Volltext

Chronic pain and depression in patients with rheumatoid arthritis: results of five - year follow - up von Lisitsyna, T A, Abramkin, A A, Veltishchev, D Yu, Seravina, O F, Kovalevskaya, O B, Zeltyn, A E, Glukhova, S I, Nasonov, E L, Krasnov, V N

Volltext

Review of 2022 American College of Rheumatology (ACR) guideline for the prevention and treatment of glucocorticoid-induced osteoporosis: what’s new? von Toroptsova, N. V., Nasonov, E. L.

Volltext

Adult Still's disease: New horizons von Nasonov, E. L., Feist, E.

Volltext

NEW POSSIBILITIES OF PHARMACOTHERAPY FOR IMMUNOINFLAMMATORY RHEUMATIC DISEASES: A FOCUS ON INHIBITORS OF INTERLEUKIN-17 von E. L. Nasonov

Volltext